BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 30481079)

  • 1. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
    Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
    J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
    Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
    J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.
    Casulo C; Day B; Dawson KL; Zhou X; Flowers CR; Farber CM; Hainsworth JD; Cerhan JR; Link BK; Zelenetz AD; Friedberg JW
    Ann Oncol; 2015 Nov; 26(11):2311-7. PubMed ID: 26362568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group.
    Méndez M; Torrente M; Sánchez-Beato M; González-Rincón J; Royuela A; Gómez-Codina J; de la Cruz-Merino L; Rueda A; Llanos M; Quero C; Rodríguez-Abreu D; Gumá J; Monsalvo S; Sabin P; Provencio M
    Hematol Oncol; 2019 Apr; 37(2):143-150. PubMed ID: 30840776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database.
    Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Hamouzova M; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
    Ann Hematol; 2018 Apr; 97(4):669-678. PubMed ID: 29318369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of event-free survival at 12 and 24 months and long-term mortality for non-Hodgkin follicular lymphoma patients: A study report from the Spanish Lymphoma Oncology Group.
    Provencio M; Royuela A; Torrente M; Pollán M; Gómez-Codina J; Sabín P; Llanos M; Gumá J; Quero C; Blasco A; Aguiar D; García-Arroyo FR; Lavernia J; Martínez N; Morales M; Saenz-Cusi Á; Rodríguez D; Calvo V; de la Cruz-Merino L; de la Cruz MÁ; Rueda A;
    Cancer; 2017 Oct; 123(19):3709-3716. PubMed ID: 28608996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
    Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
    Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
    Leonard JP; Jung SH; Johnson J; Pitcher BN; Bartlett NL; Blum KA; Czuczman M; Giguere JK; Cheson BD
    J Clin Oncol; 2015 Nov; 33(31):3635-40. PubMed ID: 26304886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.
    Gleeson M; Hawkes EA; Peckitt C; Wotherspoon A; Attygalle A; Sharma B; Du Y; Ethell M; Potter M; Dearden C; Horwich A; Chau I; Cunningham D
    Leuk Lymphoma; 2017 Aug; 58(8):1805-1813. PubMed ID: 27931133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
    Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
    Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Alonso-Álvarez S; Magnano L; Alcoceba M; Andrade-Campos M; Espinosa-Lara N; Rodríguez G; Mercadal S; Carro I; Sancho JM; Moreno M; Salar A; García-Pallarols F; Arranz R; Cannata J; Terol MJ; Teruel AI; Rodríguez A; Jiménez-Ubieto A; González de Villambrosia S; Bello JL; López L; Monsalvo S; Novelli S; de Cabo E; Infante MS; Pardal E; García-Álvarez M; Delgado J; González M; Martín A; López-Guillermo A; Caballero MD
    Br J Haematol; 2017 Sep; 178(5):699-708. PubMed ID: 28782811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance rituximab in Veterans with follicular lymphoma.
    Halwani AS; Rasmussen KM; Patil V; Morreall D; Li C; Yong C; Burningham Z; Dawson K; Masaquel A; Henderson K; DeLong-Sieg E; Sauer BC
    Cancer Med; 2020 Oct; 9(20):7537-7547. PubMed ID: 32860335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma.
    König L; Herfarth K; Hörner-Rieber J; Dietrich S; Wiegel T; Debus J; Viardot A
    Strahlenther Onkol; 2020 Aug; 196(8):705-714. PubMed ID: 32377821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
    Maurer MJ; Bachy E; Ghesquières H; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Allmer C; Chassagne-Clément C; Nicolas-Virelizier E; Sebban C; Lebras L; Sarkozy C; Macon WR; Feldman AL; Syrbu SI; Traverse-Glehan A; Coiffier B; Slager SL; Weiner GJ; Witzig TE; Habermann TM; Salles G; Cerhan JR; Link BK
    Am J Hematol; 2016 Nov; 91(11):1096-1101. PubMed ID: 27465588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study.
    Bachy E; Seymour JF; Feugier P; Offner F; López-Guillermo A; Belada D; Xerri L; Catalano JV; Brice P; Lemonnier F; Martin A; Casasnovas O; Pedersen LM; Dorvaux V; Simpson D; Leppa S; Gabarre J; da Silva MG; Glaisner S; Ysebaert L; Vekhoff A; Intragumtornchai T; Le Gouill S; Lister A; Estell JA; Milone G; Sonet A; Farhi J; Zeuner H; Tilly H; Salles G
    J Clin Oncol; 2019 Nov; 37(31):2815-2824. PubMed ID: 31339826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.